Challenges for Visual Inspection and Particle Control in Cell Therapy Products

Area of Science:

• Advanced medicinal products
• Cellular therapy manufacturing
• Quality control in biopharmaceuticals

Background:

• Cell therapy products, comprising living cells in turbid suspensions, present unique manufacturing and quality control challenges.
• Traditional methods for visible (VP) and subvisible particle (SvP) detection are often inadequate for these complex products.
• Particle generation risks are associated with manufacturing processes, single-use components, and container closure systems.

Purpose of the Study:

• To outline distinctive risks of particle generation in autologous and allogeneic cell therapies.
• To highlight limitations of existing pharmacopeial methods for particle testing.
• To propose optimized particle inspection strategies and emphasize preventative control for cell therapy products.

Main Methods:

• Review of current global regulatory requirements for particle testing (USP, Ph. Eur., JP).
• Analysis of particle sources in cell therapy manufacturing.
• Evaluation of emerging technologies like flow imaging microscopy for SvP characterization.
• Proposal of tailored visual inspection strategies for turbid cell suspensions.

Main Results:

• Identified three major sources of particles: manufacturing, single-use components, and container closure systems.
• Current pharmacopeial methods and traditional inspection approaches have limitations for cell therapy products.
• Emerging technologies and tailored strategies are needed for effective particle characterization and control.

Conclusions:

• Preventative or preemptive control, supported by risk assessment and raw material control, is the most effective strategy.
• Development of cell therapy-specific inspection standards and regulatory alignment is advocated.
• Optimized strategies and regulatory harmonization are crucial for consistent global development and patient access to cell therapies.